- For Anticoagulation in Cancer-Associated Thrombosis, Is Less More?
Saturday, August 1st, 2015
Cancer-associated thrombosis is a major cause of morbidity and mortality in patients with cancer. While low-molecular-weight heparin (LMWH) anticoagulation therapy is a standard regimen for treating acute thrombotic events in these patients, questions remain about its optimal use, including the duration of anticoagulation. ASH Clinical News invited David A. Garcia, MD, and Agnes Y. Lee, [...]
- What should the duration of anticoagulation be for a patient with idiopathic renal infarct?
Friday, May 1st, 2015
Clinical Dilemma: David Garcia, MD: